Lexaria Bioscience Corp. announced on November 20, 2024, the final 12-week body weight and blood sugar results from its recently completed diabetes animal study, WEIGHT-A24-1. All 12 study groups utilizing DehydraTECH processing outperformed the Rybelsus® control group in body weight control.
Specifically, DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top-performing groups. They demonstrated body weight loss of 11.53% and 10.65% respectively, and blood sugar reductions of 11.13% and 3.35% respectively, compared to the Rybelsus® control group.
These positive outcomes, which also showed weight-control improvement across all DehydraTECH groups during the final four weeks, provide strong support for Lexaria's pending Phase 1b Australian human study. The results indicate DehydraTECH's potential to enhance the performance of GLP-1 drugs and CBD formulations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.